SurModics (SRDX) Tops Q3 EPS by 7c, suspends previous guidance
Tweet
Share
E-mailGet Alerts SRDX Hot Sheet
Price: $42.98 --0%
Financial Fact:
Net income (loss): 2.64M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Financial Fact:
Net income (loss): 2.64M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
SurModics (NASDAQ: SRDX) reported Q3 EPS of ($0.27), $0.07 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $30.3 million versus the consensus estimate of $29.95 million.
Fiscal Year 2024 Financial Guidance
Surmodics is suspending its previously issued financial guidance for fiscal 2024 in light of the pending acquisition by GTCR.
For earnings history and earnings-related data on SurModics (SRDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMO Capital Starts Abercrombie & Fitch (anf) at Outperform
- Daedalus SPAC signs merger letter of intent with Turkish AI firm HubX
- Barnes & Noble Education (BNED) Tops Q1 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
GTCR, Earnings, Definitive Agreement, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
